期刊
AUSTRALIAN PRESCRIBER
卷 40, 期 1, 页码 9-14出版社
NATL PRESCRIBING SERVICE LTD
DOI: 10.18773/austprescr.2017.002
关键词
chronic kidney disease; drug compliance; drug costs; hyperphosphataemia; phosphate binders; pill burden
Hyperphosphataemia in patients with chronic kidney disease, particularly those on dialysis, can be ameliorated by oral phosphate binders in conjunction with dietary phosphate restriction. Although phosphate binders reduce serum phosphate in these patients, it remains uncertain whether they improve clinical outcomes. Calcium-based binders are frequently used, but their popularity is waning due to emerging evidence of accelerated vascular calcification. The use of aluminium-based binders has been limited by a perceived risk of aluminium accumulation. The non-calcium-based phosphate binders - sevelamer hydrochloride, lanthanum carbonate and sucroferric oxyhydroxide - have become available and subsidised by the Pharmaceutical Benefits Scheme for patients on dialysis. The pill burden and adverse effects (particularly gastrointestinal intolerance) associated with phosphate binders often contribute to poor medication adherence.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据